



1 Supplementary Material

2 Hydrocarbon-stapled peptide based-nanoparticles for 3 siRNA delivery

4 *Matthieu Simon*^{1,2,†}, *Nabila Laroui*^{1,†}, *Marianne Heyraud*¹, *Guillaume Laconde*¹, *Lamiaa M.A. Ali*
5 ^{1,3}, *Kevin Bourbiaux*¹, *Gilles Subra*¹, *Lubomir L. Vezekov*¹, *Baptiste Legrand*¹, *Muriel*
6 *Amblard*^{1,*}, *Nadir Bettache*^{1,*}

7 1 IBMM, Univ Montpellier, CNRS, ENSCM, 34093, Montpellier, France. matthieusimon.work@gmail.com
8 (M.S.); nabila.laroui@etu.umontpellier.fr (N.L.); marianneheyraud@hotmail.fr (M.H.);
9 guillaumelaconde@gmail.com (G.L.); lamiaa.ali@umontpellier.fr (L.M.A.A.); kevin.bourbiaux@gmail.com
10 (K.B.); gilles.subra@umontpellier.fr (G.S.); lubomir.vezekov@enscm.fr (L.L.V.);
11 baptiste.legrand@umontpellier.fr (B.L.); muriel.amblard@umontpellier.fr (M.A.);
12 nadir.bettache@umontpellier.fr (N.B.)

13 2 Present address: IRMB, CARTIGEN, CHU de Montpellier, 34090 Montpellier, France.
14 matthieusimon.work@gmail.com (M.S.)

15 3 Department of Biochemistry, Medical Research Institute, University of Alexandria, Alexandria 21561,
16 Egypt. lamiaa.ali@umontpellier.fr (L.M.A.A.)

17 * Correspondence: muriel.amblard@umontpellier.fr (M.A.); nadir.bettache@umontpellier.fr (N.B.)

18 † These authors contributed equally to this work.

19

20 **1. Materials and Methods** 2

21 **2. Results** 2

22 2.1. Cytotoxicity study of stapled peptides in reducing conditions 2

23 2.2. Gel electrophoresis of the complex JMV6337/siRNA 3

24 2.3. Luciferase activity of JMV6337 on MDA-MB-231-Luc-RFP cells..... 3

25 2.4. Cellular uptake quantified by flow cytometric analysis of MDA-MB-231 cells 4

26 2.5. Luciferase activity using siCtrl complexed with stapled peptides in MDA-MB-231-

27 Luc-RFP cells 4

28

29

30

31

32

33

34

35

36

37

Supplementary Material

38

1. Materials and Methods

39 Internalization Quantification by Flow Cytometry

40 Cells were treated or not with Stapled peptides/siCtrl-cy5 (100 nM) at N/P = 5 for JMV6582 and N/P = 2 for JMV6580 and JMV6583 for 4 h. After treatment, control and treated cells were washed once in cold Phosphate Buffer Saline (PBS), harvested and centrifuged (1300 rpm, 5 min). Cell pellet were resuspended in PBS enriched with CaCl₂ + MgCl₂ and stained with propidium iodide (1 µg.mL⁻¹) (Sigma-Aldrich Chimie, Lyon, France), a cell death indicator. Flow cytometric determination of living cells and treated positive cells was done by FACS Novocyte Flow Cytometer (ACEA Biosciences, Inc., San Diego, CA, USA) with a minimum of 20,000 living cells collected. Data were analysed with NovoExpress software (ACEA Biosciences, Inc., San Diego, CA, USA).


48

49

2. Results

50

2.1. Cytotoxicity study of stapled peptides in reducing conditions



51

52 **Figure S1** : Cytotoxicity study; human breast adenocarcinoma MDA-MB-231 cells were incubated
 53 with increasing concentrations (from 0 to 20 µM) of the stapled peptides and an excess of 10
 54 equivalents of DTT (from 0 to 200 µM), respectively, for 72 h. Results are presented as means ±
 55 standard deviations of three independent experiments performed in triplicate.

56

57


58

59

60

61

2.2. Gel electrophoresis of the complex JMV6337/siRNA




62

63 **Figure S2:** JMV6337 stapled peptide complexation with siRNA monitored by agarose gel electrophoresis
 64 analysis at N/P = 2, 5, 10 and 20.

65

66

2.3. Luciferase activity of JMV6337 on MDA-MB-231-Luc-RFP cells



67


68

69 **Figure S3:** Luciferase activity assay showing the transfection of a 21-mer siRNA targeting the expression of
 70 luciferase inside MDA-MB-231-Luc-RFP cells. The experiments were carried out with increasing amounts of
 71 siLuc (from 50 to 200 nM) complexed with the JMV6337 stapled peptide at N/P = 2. The corresponding
 72 concentrations of the JMV6337 are from 1.05 μ M to 4.2 μ M.

73

74

2.4. Cellular uptake quantified by flow cytometric analysis of MDA-MB-231 cells




75

76 **Figure S4:** Cellular uptake quantified by flow cytometric analysis of MDA-MB-231 cells treated with stapled
 77 peptide/siRNA complexes. MDA-MB 231 cells alone (upper left), cells incubated with the complex formed
 78 between JMV6580 and siCtrl-cy5 at N/P = 2(upper right), cells incubated the complex formed between JMV6582
 79 and siCtrl-cy5 at N/P = 5 (lower left) and finally, cells incubated with the complex formed between JMV6583
 80 and siCtrl-cy5 at N/P = 2 (lower right). Numbers in the profiles indicate the percentage of cells present in this area.

81
82

2.5. Luciferase activity using siCtrl complexed with stapled peptides in MDA-MB-231-Luc-RFP cells



83

84 **Figure S5:** Luciferase activity assay showing the transfection of a non-targeting 21-mer siRNA inside MDA-MB-
 85 231-Luc-RFP cells. The experiments were carried out with increasing amounts of siCtrl (from 50 to 200 nM)
 86 complexed with the stapled peptides. The corresponding concentrations of the peptides are from 1.05 μ M to 4.2

87 μM for JMV6580, from 1.4 μM to 5.6 μM for JMV6583 and from 5.25 μM to 21 μM for JMV6582. The concentration
88 of the siCtrl used in Lipofectamine condition is 50 nM.